The calpain system as a potential target for pelvic muscle reinforcement

Mariusz Blewniewski¹, Ewa Forma², Waldemar Różański¹, Magdalena Brys²

¹2nd Clinic of Urology, Medical University of Łódź, Poland
²Department of Cytobiochemistry, University of Łódź, Poland

KEY WORDS
urinary incontinence ‣ calpains ‣ calpastatin

ABSTRACT
The fascial and muscular components within the pelvic floor create a support mechanism that facilitates storage and voiding of urine. Their constituents are mainly fibrillar collagens I and III, which are responsible for maintaining tensile strength. Stretching and recoiling is enabled by the elastic fibers consisting of elastin on a scaffold of microfibrils, fibrillin-1 and -2. Calpains are intracellular Ca²⁺-dependent cysteine proteases found in almost all eukaryotes and some bacteria. Calpains display limited proteolytic activity at neutral pH, proteolyzing substrates to transform and modulate their structures and activities, and are therefore called “modulator proteases”. By making selective limited proteolytic cleavages, they modulate the activity of enzymes, including key signaling molecules, and induce specific cytoskeletal rearrangements, accounting for their roles in signal transduction and structural stabilization. Understanding these mechanisms should provide avenues for novel therapeutic strategies to treat pathological processes such as urinary incontinence and pelvic prolapse.

INTRODUCTION
Urinary incontinence (UI) in women has been claimed as a social disease thus its frequency has exceeded 5%. It is a distressing disorder, which affects mostly the elderly. Incontinence may take various forms: urge incontinence, stress incontinence, and mixed incontinence are the three main types. UI risk factors have been classified as urogynecological, constitutional, neurological, and behavioral. The anatomic structures that prevent urinary incontinence during elevations in abdominal pressure, can be divided into 2 systems: a sphincteric system and a supportive system. The action of the vesical neck and urethral sphincteric mechanisms at rest constrict the urethral lumen and keep urethral closure pressure higher than bladder pressure. The striated urogenital sphincter, the smooth muscle sphincter in the vesical neck, and the circular and longitudinal smooth muscle of the urethra all contribute to closure pressure. The mucosal and vascular tissues that surround the lumen provide a hermetic seal, and the connective tissues in the urethral wall also aid coaptation. Decreases in striated muscle sphincter fibers occur with age and parity [1, 2].

Pregnancy and childbirth are considered to be the most important UI risk factors. The persistent increased pelvic pressure, which is a result of hormone changes and increased uterine during pregnancy, leads to the damage of pelvic tissue. During vaginal delivery, the extremely stretched pelvic tissue resulted in the structure changes of muscles and supporting tissue around urethra, and ultimately induces urinary incontinence. The fascial and muscular components within the pelvic floor create a support mechanism that facilitates storage and voiding of urine. Their constituents are mainly fibrillar collagens I and III responsible for maintaining tensile strength. Stretching and recoiling is enabled by the elastic fibers consisting of elastin on a scaffold of microfibrils, fibrillin-1 and -2. In the assembly of the elastic fibers different elastin associated proteins are involved, among them the fibrulins [3-9].

Urinary incontinence is in part attributed to qualitative and quantitative changes in connective tissue of the urogenital tract. It is reported that some of the smooth muscles from women with stress urinary incontinence appeared to show atrophy, apomorphosis, or apoptosis [10]. It was discovered that women with pelvic organ prolapse had collagen degradation and elastic proteins reduction e.g. fibulin-5, elastin, smooth muscle actin, myosin heavy chain, and caldesmon [11-15].

The calpain family of proteases are widely expressed in almost all the organs. Calpains have been implicated in basic cellular processes including cytoskeletal rearrangements, different signal transduction pathways, and cell apoptosis. In pathological status, abnormal elevation of Ca²⁺ activates calpains, which accelerate the degradation of various cytoskeleton, and ultimately induces the tissue damages [16].

Although our current understanding of the mechanisms underlying these processes remains limited, recent studies have begun to shed light on this subject. Here, we discuss advances that have provided insight into where calpains fit into the elastic proteins structure, and how the activities of calpains are modulated.

Calpains
Calpains (calcium-activated non-lysosomal proteases; CAPN) were originally identified as a unique class of calcium activated proteolytic enzymes present in the cytosolic fraction of brain extracts. These proteases were later named calpains to reflect their calcium dependency and homology with the protease domain of the papain family of cysteine proteases (papain, caspasas, and cathepsins B, L, and S) [16, 17].

Molecular biological studies have shown that calpains constitute a superfamily, which exists ubiquitously in organisms ranging from humans to microorganisms, and showing limited proteolytic activity at neutral pH. Calpains result in the proteolysis of a broad spectrum of cellular proteins and a distinguishing feature of their activity is their ability to confer limited cleavage of protein substrates into stable fragments rather than complete proteolytic digestion. Calpains are regarded as bio-modulators, because properties of the substrate proteins are often modulated upon hydrolysis by calpain. Therefore, calpains are considered a representative of the intracellular modulator proteases that govern various cellular functions such as signal transduction and cell morphogenesis [18, 19].
Humans have 15 genes that encode a calpain-like protease domain, and they generate diverse kinds of calpain homologues with combinations of several functional domains such as Ca\(^{2+}\)-binding domains and transmembrane domains. Among the best studied calpains are mammalian \(\mu\)-calpain (also called calpain-1 or \(\mu\)CAPN) and m-calpain (also called calpain-2 or mCAPN), which are called the “conventional” calpains. They are mainly localized in the cytosol, show ubiquitous expression, and exhibit Ca\(^{2+}\)-dependent proteolytic activity. They are both heterodimers and consist of a large (80K) distinct \(\mu\)- and m-calpain catalytic subunits, and a common small (30K) calpain regulatory subunit. The 80K of \(\mu\)- and m-calpains isolated by dissociation in urea and that obtained by expression of the cDNA possess a full protease activity if properly folded, indicating that 30K is not essential for protease activity [18,19]. 30K also plays a role as a chaperon and is essential for 80K to have correct conformation. \(\mu\) and m-calpains dissociate into subunits in the presence of Ca\(^{2+}\). Calpains are regulated by their interacting partner, the endogenous calpain inhibitor calpastatin, which is encoded by the \(CAST\) gene [16,18,20].

**Calpain family members**

Actually, 15 human calpain genes have been numbered, \(CAPN1\)–3 and 5–16. The other two genes encode smaller regulatory proteins that associate with some of the catalytic subunits to form heterodimetric proteases. Several calpain isoforms are ubiquitously expressed, whereas many demonstrate tissue-specific expression patterns. Within the cell, the localization patterns of calpains are complex and somewhat variable, which means that their subcellular localization might be dynamically regulated and constitutes an important factor in the modulation of their functions [18, 21, 22]. Table 1 shows the calpains expression patterns in both tissues, as well as in the cell.

**Calpains structure**

The catalytic (large) and regulatory (small) subunits of conventional calpains can be divided into four (I–IV) and two domains (V-VI), respectively (Fig. 1). Domain I is present at the N-terminus of some calpains, and interacts with domain VI of the noncatalytic (small) subunits and may be important for stability. N-terminus of this domain is autolysed upon its initial activation by Ca\(^{2+}\). This results in a lower requirement for Ca\(^{2+}\), and different substrate specificity. The protease domain II is composed of two subdomains (IIa and IIb) with its substrate binding cleft in-between. It contains the active site catalytic triad Cys105, His262, and Asn286. Domain III consists of eight \(\beta\)-strands arranged in a \(\beta\)-sandwich, a structure very similar to TNF-\& and the C2-domains found in various Ca\(^{2+}\)-binding proteins.

### Table 1. Human calpain related genes, expression patterns and localization of its protein products [16, 18, 23].

| Gene   | Chr.    | Calpain protein | Protease activity/ association with 30K | Expression (highest)/ localization in the cell |
|--------|---------|-----------------|----------------------------------------|-----------------------------------------------|
| **Catalytic subunits**                                                                                                             |
| \(CAPN1\) | 11q13   | Calpain – 1     | +/-                                    | Ubiquitous (ascending and descending colon; esophagus; placenta; thyroid; tracheal) / diffuse cytoplasmic / endoplasmic reticulum / extracellular / Golgi apparatus / nucleus / plasma membrane |
| \(CAPN2\) | 1q41-q42| Calpain – 2     | +/-                                    | Ubiquitous except for mammalian erythrocytes (kidney; lung; stomach; transverse colon; tracheal) / adhesion complexes / caveolae / diffuse cytoplasmic / endoplasmic reticulum / extracellular / Golgi apparatus / lipid rafts / nucleus |
| \(CAPN3\) | 15q15   | Calpain – 3     | +/-                                    | Skeletal muscle / n.d. |
| \(CAPN5\) | 11q14   | Calpain – 5     | +/-                                    | Ubiquitous (brain; kidney; liver; lung; testis; tracheal) / diffuse cytoplasmic / nucleus |
| \(CAPN6\) | Xq23    | Calpain – 6     | -/-                                    | Placenta; embryonic muscles / n.d. |
| \(CAPN7\) | 3p24    | Calpain – 7     | N.d./-                                  | Ubiquitous / diffuse cytoplasmic / nucleus |
| \(CAPN8\) | 1q41    | Calpain – 8     | +/-                                    | Brain; digestive tract; stomach; testis / n.d. |
| \(CAPN9\) | 1q42.1-43| Calpain – 9     | +/-                                    | Digestive tracts; heart; stomach / n.d. |
| \(CAPN10\) | 2q37.3  | Calpain – 10    | N.d./n.d.                              | Ubiquitous (heart) / diffuse cytoplasmic / nucleus |
| \(CAPN11\) | 6p12    | Calpain – 11    | N.d./n.d.                              | Stomach; testis / n.d. |
| \(CAPN12\) | 19q13.2 | Calpain – 12    | N.d./n.d.                              | Hair follicle / n.d. |
| \(CAPN13\) | 2p22-p21| Calpain – 13    | N.d./n.d.                              | Ubiquitous (lung; testis) / n.d. |
| \(CAPN14\) | 2p21-22| Calpain – 14    | N.d./n.d.                              | Not detected |
| \(SOLH\ CAPN15\) | 16p13.3 | Calpain – 15    | N.d./n.d.                              | Ubiquitous (brain) / n.d. |
| \(C6orf103/CAPN16\) | 6q24.3  | Calpain – 16    | -/-                                    | Ubiquitous / n.d. |
| **Regulatory subunits**                                                                                                           |
| \(CAPNS1\) | 19q13   | CAPNS1          | No                                     | Ubiquitous (heart; interventricular septum; kidney; pancreas; prostate; skeletal muscle; testis) / diffuse cytoplasmic / endoplasmic reticulum / Golgi apparatus / nucleus / plasma membrane |
| \(CAPNS2\) | 16q13   | CAPNS2          | No                                     | Ubiquitous (bladder; esophagus; prostate; tracheal) / n.d. |
| \(CAST\)   | 5q15    | Calpastatin     | No                                     | Ubiquitous (interventricular septum) /- |

Chr. – chromosome; N.d. – not yet detected
regulated proteins such as protein kinase C isomers and synaptotagmin. This domain binds Ca\(^{2+}\) and phospholipids. Domains IV and VI in the large and small subunits, respectively, contain five sets of EF-hand Ca\(^{2+}\) binding motifs similar to those found in calmodulin. The extreme COOH-terminal fifth EF-hand motif in IV and VI cannot bind Ca\(^{2+}\) but interacts with each other to assemble heterodimers. Domain V of the small subunits appears to have a very flexible structure as a consequence of being glycine rich. This domain is thought to interact with plasma membrane and/or membrane proteins through hydrophobic interactions. Most of this domain is autolysed during activation [16, 24].

**Calpain activation and regulation**

Calpain exists in the cytosol as an inactive enzyme and translocates to membranes in response to increases in the cellular Ca\(^{2+}\) level. The Ca\(^{2+}\) concentration required for proteolytic and other activities of the calpains are much higher than the 50-300 nM Ca\(^{2+}\) that exist in living cells [25]. Studies have also described molecules that seemed to reduce the Ca\(^{2+}\) requirements of the calpains in in vitro assays. For example, isovalerylcarnitine reduces the Ca\(^{2+}\) concentration required for maximal proteolytic activity of calpain-2 and increases its specific activity. At the membrane, calpain is activated in the presence of Ca\(^{2+}\) and phospholipids. Because calpains contain calcium-binding EF-hand motifs in domains IV and VI and because domain IV of calpain-1 and domain IV of calpain-2 are different, these were originally presumed to be responsible for the calcium dependent activation of calpains [24]. Furthermore, functional studies have demonstrated that domain II alone exhibits calcium-dependent protease activity and that non-EF-hand calcium-binding sites within the protease domain act as a calcium switch to align the catalytic triad [26-28].

Autocatalytic hydrolysis of domain I take place during activation, and dissociation of 30K from 80K occurs as a result. Activated calpain or 80K hydrolyzes substrate proteins at membranes or in cytosol after release from membranes, and has a lower requirement for calcium. In the absence of Ca\(^{2+}\), two protease subdomains Ila and Ilb are separated by structural constraints imposed by domain interaction. Ca\(^{2+}\)-induced structural changes that release the constraints are prerequisite for activation to form a functional catalytic site [18, 24].

Phosphorylation of calpain might be another important mechanism for activity regulation. Calpain-2 is activated by phosphorylation of Ser50 by the ERK (extracellular signal-regulated protein kinase), mitogen-activated protein (MAP) kinase and by EGF-induced pathway whereas calpain-1 does not contain a phosphorylatable site in this region. The MAP kinase kinase MEKK1 is required for normal calpain-2 activity [29]. MEKK1 associates with focal adhesion kinase (FAK) in adhesion complexes and appears to act upstream of ERK in the regulation of calpain-2 activation [30].

Calpain activity can also be inhibited by phosphorylation. Cyclic-AMP-mediated activation of protein kinase A (PKA) can block EGF-induced activation of calpain-2. This appears to occur through phosphorylation of calpain-2 by PKA, which probably restricts domain movement and freezes calpain-2 to an inactive conformation.

![Fig. 1. Domain structures of human calpain family members. Typical calpains are composed of four domains (I–IV), whereas in the case of atypical calpains, certain domains of typical calpains have been deleted or replaced. The small subunit of calpain is composed of two domains (V and VI). Symbols used are: I – the N-terminal regulatory domain; Ila and Ilb – the protease subdomains containing the active sites, Cys and His + Asn, respectively; III - the C2-like Ca\(^{2+}\)-binding domain; IV and VI – five EF-hand containing Ca\(^{2+}\)-binding PEF domain; V – glycine-rich hydrophobic domain; MIT – microtubule interacting and trafficking domain; NS, IS1, and IS2 – calpain-3-specific sequences; SOH – SOL subfamily homology domain; SOLH – small optic lobe homology domain; Zn–Zn-finger motif-containing domain.](image-url)
The residues in calpain-2 (Ser369 and Thr370) that appear to be the protein kinase A targets are conserved in other calpains, which suggests that phosphorylation of domain III represents yet another mechanism for regulating calpain activity [31, 32].

In addition, PKA reduces calpain-2 activity by blocking phosphatidylinositol-4,5-bisphosphate (PIP2) binding in the C2 domain of calpain. Recent observations indicate that PIP2 acts as a cofactor for calpain-2 and that phosphorylation by ERK or PAK alters the cellular distribution of the enzyme to modulate activity. Localization of calpain-2 at the plasma membrane, through PIP2 anchorage, is important for the activation of the protease [33, 34].

The binding of phospholipids also decreases the calcium requirement for calpains in vitro [35]. During the initial studies on purifying calpain-2, it was discovered that muscle extracts having calpain activity also contained a calpain inhibitor [36]. The name calpastatin was proposed for this inhibitor by Takashi Murachi in 1979. It consists of an N-terminal L domain that contains an N-terminal XL region, and four repetitive inhibitory domains (I–IV). The intrinsically unstructured nature of calpastatin allows it to reversibly inhibit up to four calpain heterodimers [20].

The equilibrium binding of calpains to calpastatin is extremely pH sensitive and decreases as pH decreases. Immunolocalization results suggest that the calpains and calpastatin are frequently localized in cells, so the cells must possess some mechanism to allow calpain activity in the presence of calpastatin. Otherwise, increased CA2+ concentrations would cause calpastatin binding before the calpains could initiate any proteolytic activity [28, 37].

Experiments of the binding of autolytic fragments of calpains to calpastatin indicated that calpastatin bound to both domains IV and VI of the calpain molecule. Subsequent studies using expressed subdomains of the calpastatin molecule showed that a 14-amino acid subdomain was conserved around the four domains of the calpastatin molecule and bound specifically to domain IV of calpain in a Ca2+-dependent manner [36].

Research showed that optimal conditions for in vitro calpain activity were pH 7.5 at 25°C. However, this condition does not naturally occur in a slaughtered animal. Minimal activity is seen at 1.5 cm below the urinary meatus. In the studied material mucosa, submucosa, connective tissue, and smooth muscle were contained.

In turn, Chen and coworkers studied the expression of calpain-1 and calpain-2 in the vaginal walls of women with and without uroterovaginal prolapse [45]. They conclude that calpain expression may be compromised in the anterior vaginal wall of women with uroterovaginal prolapse who have abnormal histologic changes in the vaginal connective tissues or have anterior vaginal laxity.

Although the mechanism of calpain action in these tissues is not clear, it can be assumed that it is linked to proteolysis of structural proteins, both smooth muscle and connective tissue.

Croll et al., found that the calmodulin binding proteins, caldesmon and calponin, are cleaved by both major isoforms of calpain in vitro [17]. Qualitatively, the cleavage pattern of each substrate is unchanged by the presence or absence of calmodulin suggesting that the interaction between calmodulin and these calmodulin-binding proteins does not alter substrate recognition by calpain. Authors conclude that calmodulin-binding domains do not provide substrate recognition sites for calpains. It seems likely that the calmodulin-like regions of calpain function to bind calcium and to regulate enzyme conformation as required for activity and that they do not interact directly with most substrates [46]. Similar results were obtained for calpain by Tsuchakawa and coworkers [47].

In turn, Yoshimoto et al., suggested that acidic calponin, an actin binding protein expressed in smooth muscle, is also cleaved by calpain, and this protein might be involved in the calpain-regulated actin cytoskeleton. Further proteins degraded by calpain-2 are actin and vimentin [48].

Yoshida et al., demonstrated proteolysis of two important cytoskeletal proteins, actin and vimentin, in the lens fiber cells by calpain [49].

Connective tissue is the most important part of pelvic supportive tissue, which maintains the flexibility and toughness of pelvic floor. Collagen secreted by fibroblast is the major compartment of connective tissue. It is reported that collagenolytic activity might be related with the occurrence of urinary incontinence [50-52].

Von Wnuck Lipinski and coworkers found that collagen I and III fragments proteolytically released from the extracellular matrix...
by matrix metalloproteinases may propagate apoptosis of smooth muscle cells by calpain-mediated inactivation of anti-apoptotic proteins such as X-chromosome-linked inhibitor of apoptosis (xIAP) [53, 54]. They suggest that degraded collagen fragments simultaneously activated an apoptotic pathway triggered by calpain/caspase activation and a survival pathway triggered by NF-κB activation. The survival pathway was dominant over the apoptotic as substantial cell death took place only after inactivation of NF-κB.

CONCLUSIONS

Calpain activity contributes to remodeling of the actin cytoskeleton, cell migration, and oncogenic transformation. Structure-function relationships for various calpain family members is now providing valuable insights into the complex regulation of these proteases and should help to design therapies for disorders involving calpain activation in the future.

REFERENCES

1. Huskier S: A systematic review of overweight and obesity as risk factors and targets for clinical intervention for urinary incontinence in women. Neurourology and Urodynamics 2008; 27: 749-757.
2. Dumoelin C, Hay-Smith J: Pelvic floor muscle training versus no treatment for urinary incontinence in women. A Cochrane systematic review. Eur J Phys Rehabil Med 2008; 44: 47-63.
3. Greer WJ, Richter HE, Bartolucci AA, Burgio KL: Obesity and pelvic floor disorders: a systematic review. Obstet Gynecol 2008; 112: 341-349.
4. Wing RR, West DS, Grady D, et al: Effect of weight loss on urinary incontinence in overweight and obese women: results at 12 and 18 months. J Urol 2010; 184: 1005-1010.
5. Nygaard I, Barber MD, Burgio KL, et al: Pelvic Floor Disorders Network. Prevalence of symptomatic pelvic floor disorders in US women. JAMA 2008; 300: 1311-1316.
6. Söderberg MW, Byström B, Hammarström M, et al: Decreased gene expression of fibrillin-1 in stress urinary incontinence. Neurourology and Urodynamics 2010; 29: 476-481.
7. Söderberg MW, Byström B, Kalamajski S, Malmström A, Ekman-Ordeberg G: Gene expression of small leucine-rich repeat proteoglycans and fibrillin-5 are decreased in pelvic organ prolapse. Mol Hum Reprod 2009; 15: 251-257.
8. Drewes PG, Yanagisawa H, Starcher B, et al: Organ gel formation in fibulin-5 knockout mice: pregnancy-induced changes in elastic fiber homeostasis in mouse vagina. Am J Pathol 2007; 170: 578-589.
9. Jung HJ, Jeon MJ, Yim GW, et al: Changes in expression of fibulin-5 and lysyl oxidase-like-1 associated with pelvic organ prolapse. Eur J Obstet Gynecol Reprod Biol 2009; 145: 117-122.
10. Budatha M, Roshanravan S, Zheng Q, et al: Extracellular matrix proteases contribute to progression of pelvic organ prolapse in mice and humans. J Clin Invest 2011; 121: 2048-2059.
11. Boreham MK, Miller RT, Schaffer JJ, Word RA: Smooth muscle myosin heavy chain and caldesmon expression in the anterior vaginal wall of women with and without pelvic organ prolapse. Am J Obstet Gynecol 2001; 185: 944-952.
12. Takacs P, Guaitieri M, Nassiri M, et al: Caldesmon expression is decreased in women with anterior vaginal wall prolapse: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20: 985-990.
13. Takacs P, Guaitieri M, Nassiri M, et al: Differential expression of smooth muscle regulatory proteins in the uterosacral ligaments of women with uterine prolapse. Am J Obstet Gynecol 2010; 202: 620.e1-5.
14. Takacs P, Nassiri M, Miciana A, et al: Fibulin-5 expression is decreased in women with anterior vaginal wall prolapse. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20: 207-211.
15. Klutke J, Ji Q, Campeau J, et al: Decreased endopelvic fascia elastin content in uterine prolapse. Acta Obstet Gynecol Scand 2008; 87: 111-115.
16. Storr SJ, Carragher NO, Frame MC, et al: The calpain system and cancer. Nat Rev Cancer 2011; 11: 364-374.
17. Croall DE, Chacko S, Wang Z: Cleavage of caldesmon and calpain by calpain: substrate recognition is not dependent on calmodulin binding domains. Biochim Biophys Acta 1996; 1286: 276-284.
18. Sorimachi H, Hata S, Ono Y: Expanding members and roles of the calpain superfamily and their genetically modified animals. Exp Anim 2010; 59: 549-566.
19. Bertipaglia I, Carafoi E: Calpains and human disease. Subcell Biochem 2007; 45: 29-53.
20. Wendt A, Thompson VF, Goll J: Interaction of calpastatin with calpain: a review. Biol Chem 2004; 385: 465-472.
21. Goll DE, Thompson VF, Li H, et al: The calpain system. Physiol Rev 2003; 83: 731-801.
22. Suzuki K, Hata S, Kawabata Y, Sorimachi H: Structure, activation, and biology of calpain. Diabetes 2004; 53: 12-28.
23. Franco SJ, Huttonlocher A: Regulating cell migration: calpains make the cut. J Cell Sci 2005; 118: 3829-3838.
24. Benyamin Y: The structural basis of calpain behavior. FEBS J 2006; 273: 3413-3414.
25. Maravall M, Mainen ZF, Sabatini BL, Svoboda K: Estimating intracellular calcium concentrations and buffering without wavelength ratioing. Biophys J 2000; 78: 2665-2667.
26. Hata S, Sorimachi H: New biology of calpain in relation with intracellular membrane systems. Seikagaku 2007; 79: 46-50.
27. Moldoveanu T, Gehring K, Green DR: Concerted multi-pronged attack by calpastatin to occlude the catalytic cleft of heterodimeric calpains. Nature 2008; 456: 404-408.
28. Moldoveanu T, Jia Z, Davies PL: Calpain activation by cooperative Ca2+ binding to calpastatin to occlude the catalytic cleft of heterodimeric calpains. Nature 2008; 456: 404-408.
29. Cuevas BD, Abell AN, Witowsky JA, et al: MEK1 regulates calpain-dependent proteolysis of focal adhesion proteins for rear-end detachment of migrating fibroblasts. EMBO J 2003; 22: 3346-3355.
30. Glading A, Uferall F, Keyse SM, et al: Membrane proximal ERK signaling is required for M-calpain activation downstream of epidermal growth factor receptor signaling. J Biol Chem 2001; 276: 23341-23348.
31. Shiraha H, Glading A, Chou J, et al: Activation of m-calpain (calpain II) by epidermal growth factor is limited by protein kinase A phosphorylation of m-calpain. Mol Cell Biol 2002; 22: 2716-2727.
32. Smith SD, Jia Z, Huynh KK, et al: Glutamate substitutions at a PKA consensus site are consistent with inactivation of calpain by phosphorylation. FEBS Lett 2003; 542: 115-118.
33. Leloup I, Shao H, Bae YH, et al: m-Calpain activation is regulated by its membrane localization and by its binding to phosphatidylinositol 4, 5-bisphosphate. J Biol Chem 2010; 285: 33549-33566.
34. Shao H, Chou J, Baty CJ, et al: Spatial localization of m-calpain to the plasma membrane by phosphorynsostide bisphosphate binding during epidermal growth factor-receptor-mediated activation. Mol Cell Biol 2006; 26: 5481-5496.
35. Tompa P, Tóth-Boconádi R, Friedrich P: Frequency decoding of fast calcium oscillations by calpain. Cell Calcium 2001; 29: 161-170.
36. Cong J, Thompson VF, Goll DE: Immunoaffinity purification of the calpains. Protein Expr Purif 2002; 25: 285-290.
37. Hanna RA, Campbell R L, Davies PL: Calcium-bound structure of calpain and its mechanism of inhibition by calpastatin. Nature 2008; 456: 409-412.
38. Araújo IM, Carreira BP, Carvalho CM, Carvalho AP: Calpains and delayed calpain activation and targets for clinical intervention for urinary incontinence in women. A Cochrane systematic review. Eur J Urol 2008; 45: 3413-3414.
42. Tang DD: Intermediate filaments in smooth muscle. Am J Physiol Cell Physiol 2008; 294: 869-878.
43. Wang R, Li Q, Tang DD: Role of vimentin in smooth muscle force development. Am J Physiol Cell Physiol 2006; 291: 483-489.
44. Lametsch R, Roepstorff P, Møller HS, Bendixen E: Identification of myofibrillar substrates for m-calpain. Meat Science 2004; 68: 515-521.
45. Wu Y, Zhang L, Jin H, Zhou J, Xie Z: The role of calpain-calpastatin system in the development of stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2010; 21: 63-68.
46. Chen GD, Chen YC, Lin LY: Different expression of calpains in the anterior vaginal wall of women with and without uterovaginal prolapse. J Soc Gynecol Investig 2004; 11: 113-117.
47. Rozenblum GT, Gimona M: Calponins: adaptable modular regulators of the actin cytoskeleton. Int J Biochem Cell Biol 2008; 40: 1990-1995.
48. Tsunekawa S, Takahashi K, Abe M, Hiwada K, et al: Calpain proteolysis of free and bound forms of calponin, a troponin T-like protein in smooth muscle. FEBS Lett 1989; 250: 493-496.
49. Yoshimoto R, Hori M, Ozaki H, Karaki H: Proteolysis of acidic calponin by mu-calpain. J Biochem 2000; 128: 1045-1049.
50. Yoshida H, Murachi T, Tsukahara I: Degradation of actin and vimentin by calpain II, a Ca2+-dependent cysteine proteinase, in bovine lens. FEBS Lett 1984; 170: 259-262.
51. Gafni J, Cong X, Chen SF, et al: Calpain-1 cleaves and activates caspase-7. J Biol Chem 2009; 284: 25441-25449.
52. Martinez JA, Zhang Z, Svetlov SI, et al: Calpain and caspase processing of caspase-12 contribute to the ER stress-induced cell death pathway in differentiated PC12 cells. Apoptosis 2010; 15: 1480-1493.
53. Tan Y, Wu C, De Veyra T, Greer PA: Ubiquitous calpains promote both apoptosis and survival signals in response to different cell death stimuli. J Biol Chem 2006; 281: 17689-17698.
54. von Wnuck Lipinski K, Keul P, Ferri N, et al: Integrin-mediated transcriptional activation of inhibitor of apoptosis proteins protects smooth muscle cells against apoptosis induced by degraded collagen. Circ Res 2006; 98: 1490-1497.
55. von Wnuck Lipinski K, Keul P, Lucke S, et al: Degraded collagen induces calpain-mediated apoptosis and destruction of the X-chromosome-linked inhibitor of apoptosis (XIAP) in human vascular smooth muscle cells. Cardiovasc Res 2006; 69: 697-705.

Correspondence
Mariusz Blewniewski
2nd Clinic of Urology
Medical University of Łódź
62, Pabianicka Street
93-513 Łódź, Poland
phone: +48 601 32 28 32
blewniewski@poczta.onet.pl